 Steven Bines
Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 5 | 2017 | 64 | 1.130 |
Why?
| | Sentinel Lymph Node Biopsy | 2 | 2017 | 19 | 0.500 |
Why?
| | Aptitude Tests | 1 | 2013 | 3 | 0.490 |
Why?
| | General Surgery | 2 | 2013 | 62 | 0.480 |
Why?
| | Genetic Therapy | 2 | 2013 | 94 | 0.470 |
Why?
| | Ileal Neoplasms | 1 | 2011 | 3 | 0.420 |
Why?
| | Skin Neoplasms | 2 | 2013 | 86 | 0.420 |
Why?
| | Clinical Competence | 1 | 2013 | 284 | 0.390 |
Why?
| | Herpesvirus 1, Human | 1 | 2010 | 3 | 0.390 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 29 | 0.390 |
Why?
| | Genetic Vectors | 1 | 2010 | 66 | 0.380 |
Why?
| | Laparoscopy | 1 | 2011 | 193 | 0.360 |
Why?
| | Rosaniline Dyes | 1 | 2008 | 3 | 0.350 |
Why?
| | Radioisotopes | 1 | 2008 | 16 | 0.350 |
Why?
| | Neoplasm Staging | 2 | 2017 | 457 | 0.340 |
Why?
| | Neoplasm Invasiveness | 1 | 2008 | 92 | 0.340 |
Why?
| | Breast Neoplasms | 1 | 2008 | 435 | 0.240 |
Why?
| | Immunotherapy | 2 | 2013 | 75 | 0.230 |
Why?
| | Cancer Vaccines | 2 | 2012 | 16 | 0.210 |
Why?
| | Carcinoma, Renal Cell | 2 | 2012 | 46 | 0.200 |
Why?
| | Watchful Waiting | 1 | 2017 | 9 | 0.160 |
Why?
| | Lymph Node Excision | 1 | 2017 | 36 | 0.160 |
Why?
| | Clinical Clerkship | 2 | 2013 | 29 | 0.150 |
Why?
| | Opioid-Related Disorders | 1 | 2017 | 63 | 0.140 |
Why?
| | Pain Management | 1 | 2017 | 145 | 0.140 |
Why?
| | Humans | 13 | 2017 | 32988 | 0.140 |
Why?
| | Lymph Nodes | 2 | 2017 | 84 | 0.140 |
Why?
| | Gastroscopy | 1 | 2015 | 10 | 0.130 |
Why?
| | Gastrostomy | 1 | 2015 | 12 | 0.130 |
Why?
| | Chronic Disease | 1 | 2017 | 554 | 0.130 |
Why?
| | Mental Disorders | 1 | 2017 | 206 | 0.130 |
Why?
| | Analgesics, Opioid | 1 | 2017 | 224 | 0.130 |
Why?
| | Patient Safety | 1 | 2015 | 55 | 0.130 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2015 | 78 | 0.120 |
Why?
| | Retrospective Studies | 3 | 2017 | 3835 | 0.120 |
Why?
| | Animals, Laboratory | 1 | 2013 | 3 | 0.120 |
Why?
| | Adult | 5 | 2017 | 9848 | 0.120 |
Why?
| | Head and Neck Neoplasms | 1 | 2015 | 141 | 0.120 |
Why?
| | Vitiligo | 1 | 2013 | 2 | 0.120 |
Why?
| | Hypopigmentation | 1 | 2013 | 2 | 0.120 |
Why?
| | Mutant Proteins | 1 | 2013 | 9 | 0.120 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2013 | 9 | 0.120 |
Why?
| | Animals | 6 | 2013 | 5371 | 0.120 |
Why?
| | Education, Medical | 1 | 2013 | 48 | 0.120 |
Why?
| | Autoimmunity | 1 | 2013 | 22 | 0.120 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 35 | 0.120 |
Why?
| | Students, Medical | 1 | 2013 | 52 | 0.120 |
Why?
| | Immunotherapy, Active | 1 | 2012 | 4 | 0.110 |
Why?
| | Middle Aged | 5 | 2017 | 11219 | 0.110 |
Why?
| | Laparoscopes | 1 | 2011 | 3 | 0.110 |
Why?
| | Kidney Neoplasms | 1 | 2012 | 77 | 0.100 |
Why?
| | Biopsy, Needle | 1 | 2011 | 112 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 244 | 0.100 |
Why?
| | Cytopathogenic Effect, Viral | 1 | 2010 | 3 | 0.100 |
Why?
| | Defective Viruses | 1 | 2010 | 2 | 0.100 |
Why?
| | Injections, Intralesional | 1 | 2010 | 34 | 0.100 |
Why?
| | Immunohistochemistry | 1 | 2011 | 471 | 0.090 |
Why?
| | Clinical Protocols | 1 | 2010 | 73 | 0.090 |
Why?
| | Virus Replication | 1 | 2010 | 98 | 0.090 |
Why?
| | Prostatic Neoplasms | 1 | 2010 | 125 | 0.090 |
Why?
| | Coloring Agents | 1 | 2008 | 16 | 0.090 |
Why?
| | Adenocarcinoma | 1 | 2010 | 231 | 0.090 |
Why?
| | Drug Hypersensitivity | 1 | 2008 | 19 | 0.090 |
Why?
| | Colorectal Neoplasms | 1 | 2010 | 128 | 0.090 |
Why?
| | Mice | 2 | 2013 | 1958 | 0.080 |
Why?
| | Prospective Studies | 2 | 2013 | 2002 | 0.080 |
Why?
| | Patient Selection | 1 | 2010 | 261 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 177 | 0.080 |
Why?
| | Research Design | 1 | 2010 | 244 | 0.080 |
Why?
| | Treatment Outcome | 3 | 2015 | 4036 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2008 | 358 | 0.080 |
Why?
| | Linear Models | 1 | 2008 | 275 | 0.080 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2011 | 319 | 0.080 |
Why?
| | Male | 6 | 2017 | 17726 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 592 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 899 | 0.070 |
Why?
| | Aged | 4 | 2017 | 10542 | 0.070 |
Why?
| | Follow-Up Studies | 1 | 2011 | 2053 | 0.070 |
Why?
| | Risk Assessment | 1 | 2008 | 814 | 0.070 |
Why?
| | Female | 5 | 2017 | 18423 | 0.060 |
Why?
| | Cohort Studies | 1 | 2008 | 2077 | 0.060 |
Why?
| | Vaccines, DNA | 2 | 2012 | 10 | 0.050 |
Why?
| | Young Adult | 2 | 2017 | 2287 | 0.050 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 368 | 0.040 |
Why?
| | Postoperative Complications | 2 | 2017 | 1117 | 0.040 |
Why?
| | Pain Clinics | 1 | 2017 | 6 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2017 | 8 | 0.040 |
Why?
| | Lymphedema | 1 | 2017 | 5 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2017 | 101 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2017 | 228 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 494 | 0.040 |
Why?
| | Survival Analysis | 1 | 2017 | 372 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2017 | 162 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 387 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2017 | 5249 | 0.040 |
Why?
| | Ultrasonography | 1 | 2017 | 215 | 0.040 |
Why?
| | Palliative Care | 1 | 2017 | 158 | 0.040 |
Why?
| | Prognosis | 1 | 2017 | 1011 | 0.030 |
Why?
| | Antigens | 1 | 2013 | 28 | 0.030 |
Why?
| | Medical Oncology | 1 | 2013 | 37 | 0.030 |
Why?
| | Antigen-Presenting Cells | 1 | 2013 | 19 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 120 | 0.030 |
Why?
| | Vaccination | 1 | 2013 | 45 | 0.030 |
Why?
| | Transfection | 1 | 2013 | 150 | 0.030 |
Why?
| | Forecasting | 1 | 2013 | 136 | 0.030 |
Why?
| | Dendritic Cells | 1 | 2013 | 65 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2013 | 129 | 0.030 |
Why?
| | Skin | 1 | 2013 | 136 | 0.030 |
Why?
| | Disease Management | 1 | 2013 | 138 | 0.030 |
Why?
| | Peptides | 1 | 2013 | 115 | 0.030 |
Why?
| | Models, Immunological | 1 | 2012 | 9 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 216 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2013 | 235 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2012 | 34 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2013 | 229 | 0.030 |
Why?
| | Anxiety | 1 | 2013 | 180 | 0.030 |
Why?
| | Phenotype | 1 | 2013 | 385 | 0.030 |
Why?
| | Societies, Medical | 1 | 2013 | 214 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 563 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2013 | 298 | 0.020 |
Why?
| | Inflammation | 1 | 2013 | 396 | 0.020 |
Why?
| | Models, Animal | 1 | 2010 | 147 | 0.020 |
Why?
| | Disease Progression | 1 | 2013 | 870 | 0.020 |
Why?
| | United States | 1 | 2013 | 2632 | 0.020 |
Why?
|
|
Bines's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|